FHL1在乳腺癌紫杉联合蒽环类药物新辅助化疗中的预测价值
|
摘要
新辅助化疗(Neoadjuvant chemotherapy,NCT)已经成为乳腺癌综合治疗手段中一个重要的组成部分,然而,大约有27%左右的患者不能从新辅助化疗当中真正获益。寻找能够预测化疗反应性的生物学因子,可以为临床给不同患者施行个体化治疗提供必要的参考依据。该研究针对一个新发现的抑癌基因——FHL1(four and a half LIM domains 1,FHL1)进行了临床与基础研究,以期发现FHL1在乳腺癌紫杉联合蒽环类药物新辅助化疗中的预测价值,为临床提供一个新的化疗反应预测性指标。本研究共分三个部分进行。
第一部分,以2006年至2008年在解放军总医院普通外科接受紫杉联合蒽环类药物新辅助化疗的164名患者为研究对象,回顾性分析他们的临床及病理资料,共获得67名患者化疗前、后完整配对的组织切片,为其进行FHL1免疫组化染色,运用秩和检验分析化疗前、后FHL1表达水平的改变,以及化疗前FHL1表达水平与患者临床、病理缓解率的相关性。结果发现,FHL1表达水平在化疗后明显下调;化疗前FHL1表达水平越高,化疗有效性越低。
第二部分,通过构建FHL1过量表达稳定转染乳腺癌细胞株(MCF-7-FHL1)和空白载体细胞株(MCF-7-control),采用生长曲线(结晶紫)方法,检测外源性FHL1对于不同药物化疗敏感性的影响;利用内源性表达少量FHL1的MCF-7细胞株和不表达FHL1的T47D细胞株,检测内源性FHL1对于不同药物化疗敏感性的影响。结果发现,无论是内源性还是外源性FHL1表达,对乳腺癌细胞株的化疗敏感性均未见明确影响。同时发现,多西他赛(Docetaxel)对乳腺癌细胞的生长抑制作用较吡柔比星(THP)弱,亦即,乳腺癌细胞对Docetaxel的药物敏感性较之对THP的敏感性低。
第三部分,将MCF-7-FHL1细胞株用空白对照、Docetaxel单药、FHP单药以及Docetaxel+THP联合用药四种处理方式处理后,采用Western Blot方法分析各组细胞中FHL1表达水平的改变。结果发现,多西他赛在使FHL1表达下调中起关键性作用。
综上所述,FHL1作为一个抑癌基因,其表达在乳腺癌新辅助化疗中具有重要的预测价值。乳腺癌肿瘤组织内的FHL1表达越高,化疗有效率越低,FHL1表达阴性的患者,临床有效率可达100%。此外,Docetaxel可以降低肿瘤组织中FHL1的表达,可能增加肿瘤扩散和转移的机会。
Neoadjuvant chemotherapy(NCT)has been an important component of multimodality treatment for Breast cancer.However,about 27%of the patients did not benefit from this clinical treatment and,predictive factors of response were not defined yet.This study was designed to evaluate the value of the four and a half LIM domains 1(FHL1)to predict response in stageⅡandⅢbreast cancer patients treated with taxane and anthracycline combination as neoadjuvant setting.FHL1 was regard as a cancer suppressor gene in most human tumor.This study was divided into three part.
Firt part of all,164 patients received preoperative Pirarubicin(THP)(50 mg/m2)in i.v.infusion in D1 and combination with Docetaxel(75 mg/m2)in D2 every 3 weeks after core needle biopsy.Their clinical and pathological material were retrospectively analyzed,and slides of 67 patients have been got matched at last.Clinical and pathologic response rates were measured after preoperative therapy.Expression level of FHL1 was investigated in immunohistochemistry (IHC)stains.We evaluated the response rate to neoadjuvant chemotherapy and the predictive significance of immunohistochemical(FHL1)outcomes.As a result, FHL1 protein expression decreased after chemotherapy,overexpression was associated with lower clinical response rates.
The second part,FLAG-tagged FHL1 and empty vector was transfected into breast cancer cells,MCF-7,and the stably transfected cell strains was constructed. MCF-7 cells transfected with FHL1 and empty vector both were diveded into four groups,and then respectively cultured in regular medium,and gave different chemotherapy agents seperately.At specified times,cell numbers were determined by crystal violet assay.Values shown are mean±SD of triplicate measurements and have been repeated 3 times with similar results.Results showed that,both Docetaxel and THP could suppress the growth of cells with or without FHL1-overexpression,and Docetaxel led lower decrease in the number of alive cells than THP.FHL1 had not significantly affect on the response to different chemotherapy agents of the cells.
The third part,cells stably transfected with FHL1 were treated with four different agent regimen,include blank control.Proteins extracted from above cells lines were analyzed by Western blot with anti-FHL1.The densitometric quantitation of FHL1 bands normalized to GAPDH.The results showed that Docetaxel was the main contributor to decrease the expression of FHL1.
In sum,as a tumor suppressor,expression of FHL1 in breast cancer was an important predictive factor in neoadjuvant chemotherapy.And higher level of FHL1 in breast tumor means lower clinical respons to chemotherapy.Docetaxel could decrease the expression of FHL1 in breast tumor,may promote anchorage-independent cell growth and migration.
第一部分,以2006年至2008年在解放军总医院普通外科接受紫杉联合蒽环类药物新辅助化疗的164名患者为研究对象,回顾性分析他们的临床及病理资料,共获得67名患者化疗前、后完整配对的组织切片,为其进行FHL1免疫组化染色,运用秩和检验分析化疗前、后FHL1表达水平的改变,以及化疗前FHL1表达水平与患者临床、病理缓解率的相关性。结果发现,FHL1表达水平在化疗后明显下调;化疗前FHL1表达水平越高,化疗有效性越低。
第二部分,通过构建FHL1过量表达稳定转染乳腺癌细胞株(MCF-7-FHL1)和空白载体细胞株(MCF-7-control),采用生长曲线(结晶紫)方法,检测外源性FHL1对于不同药物化疗敏感性的影响;利用内源性表达少量FHL1的MCF-7细胞株和不表达FHL1的T47D细胞株,检测内源性FHL1对于不同药物化疗敏感性的影响。结果发现,无论是内源性还是外源性FHL1表达,对乳腺癌细胞株的化疗敏感性均未见明确影响。同时发现,多西他赛(Docetaxel)对乳腺癌细胞的生长抑制作用较吡柔比星(THP)弱,亦即,乳腺癌细胞对Docetaxel的药物敏感性较之对THP的敏感性低。
第三部分,将MCF-7-FHL1细胞株用空白对照、Docetaxel单药、FHP单药以及Docetaxel+THP联合用药四种处理方式处理后,采用Western Blot方法分析各组细胞中FHL1表达水平的改变。结果发现,多西他赛在使FHL1表达下调中起关键性作用。
综上所述,FHL1作为一个抑癌基因,其表达在乳腺癌新辅助化疗中具有重要的预测价值。乳腺癌肿瘤组织内的FHL1表达越高,化疗有效率越低,FHL1表达阴性的患者,临床有效率可达100%。此外,Docetaxel可以降低肿瘤组织中FHL1的表达,可能增加肿瘤扩散和转移的机会。
Neoadjuvant chemotherapy(NCT)has been an important component of multimodality treatment for Breast cancer.However,about 27%of the patients did not benefit from this clinical treatment and,predictive factors of response were not defined yet.This study was designed to evaluate the value of the four and a half LIM domains 1(FHL1)to predict response in stageⅡandⅢbreast cancer patients treated with taxane and anthracycline combination as neoadjuvant setting.FHL1 was regard as a cancer suppressor gene in most human tumor.This study was divided into three part.
Firt part of all,164 patients received preoperative Pirarubicin(THP)(50 mg/m2)in i.v.infusion in D1 and combination with Docetaxel(75 mg/m2)in D2 every 3 weeks after core needle biopsy.Their clinical and pathological material were retrospectively analyzed,and slides of 67 patients have been got matched at last.Clinical and pathologic response rates were measured after preoperative therapy.Expression level of FHL1 was investigated in immunohistochemistry (IHC)stains.We evaluated the response rate to neoadjuvant chemotherapy and the predictive significance of immunohistochemical(FHL1)outcomes.As a result, FHL1 protein expression decreased after chemotherapy,overexpression was associated with lower clinical response rates.
The second part,FLAG-tagged FHL1 and empty vector was transfected into breast cancer cells,MCF-7,and the stably transfected cell strains was constructed. MCF-7 cells transfected with FHL1 and empty vector both were diveded into four groups,and then respectively cultured in regular medium,and gave different chemotherapy agents seperately.At specified times,cell numbers were determined by crystal violet assay.Values shown are mean±SD of triplicate measurements and have been repeated 3 times with similar results.Results showed that,both Docetaxel and THP could suppress the growth of cells with or without FHL1-overexpression,and Docetaxel led lower decrease in the number of alive cells than THP.FHL1 had not significantly affect on the response to different chemotherapy agents of the cells.
The third part,cells stably transfected with FHL1 were treated with four different agent regimen,include blank control.Proteins extracted from above cells lines were analyzed by Western blot with anti-FHL1.The densitometric quantitation of FHL1 bands normalized to GAPDH.The results showed that Docetaxel was the main contributor to decrease the expression of FHL1.
In sum,as a tumor suppressor,expression of FHL1 in breast cancer was an important predictive factor in neoadjuvant chemotherapy.And higher level of FHL1 in breast tumor means lower clinical respons to chemotherapy.Docetaxel could decrease the expression of FHL1 in breast tumor,may promote anchorage-independent cell growth and migration.
引文
1 程虹等译.乳腺及女性生殖器官肿瘤病理学和遗传学.北京:人民卫生出版社,2006:1-135.
2 Olopade OI,Grushko TA,Nanda R,et al.Advances in breast cancer:pathways to personalized medicine.Clin Cancer Res.2008,14(24):7988-99.
3 Mauri D,Pavlidis N,Ioannidis JP:Neoadjuvant versus adjuvant systemic treatment in breast cancer:A meta-analysis.J Natl Cancer Inst.2005,97:188-194.
4 Pritchard KI,Messersmith H,Elavathil L,et al.HER-2 and topoisomerase Ⅱ as predictors of response to chemotherapy.J Clin Oncol.2008,26(5):736-44.
5 Rody A,Kam T,G(?)tje R,et al.Gene expression profiling of breast cancer patients treated with docetaxel,doxorubicin,and cyclophosphamide within the GEPARTRIO trial:HER-2,but not topoisomerase Ⅱ alpha and microtubule-associated protein tau,is highly predictive of tumor response.Breast,2007,16(1):86-93.
6 Li X,Jia ZY,Shen YQ,et al.Coordinate suppression of Sdpr and Fhl1expression in tumors of the breast,kidney,and prostate.Cancer Sci,2008,99(7):1326-1333.
7 杨学宁,吴一龙.实体瘤治疗疗效评价标准——EC I ST.循证医学,2004,4(2):85-111.
8 Kang MA,Jeoung NH,Kim JY,et al.Up-regulation of skeletal muscle LIM protein 1 gene by 25-hydroxycholesterol may mediate morphological changes of rat aortic smooth muscle cells.Life Sciences,2007,80:460-467.
9 Michelsen JW,Sewell AK,Louis HA et al.Mutational analysis of the metal sites in an LIM domain.J Biol Chem 1994;269:11 108-13.
10 Schmeichel KL,Beckerle MC.Molecular dissection of a LIM domain.Mol Biol Cell 1997;8:219-30
11 Kadrmas JL,Beckerle MC.The LIM domain:from the cytoskeleton to the nucleus.Nat Rev Mol Cell Biol 2004;5:920-31.
12 Schmeichel KL,Beckerle MC.The LIM domain is a modular proteinbinding interface.Cell,1994,79:211-19.
13 Feuerstein R,Wang X,Song D,Cooke NE,Liebhaber SA.The LIM/double zinc-finger motif functions as a protein dimerization domain.Proc Natl Acad Sci USA 1994;91:10 655-9.
14 Morgan MJ,Whawell SA.The structure of the human LIM protein ACT gene and its expression in tumor cell lines.Biochemical and Biophysical Research Communications,2000,273 (2):776-783.
15 Robinson PA,Brown S,McGrath MJ,et al.Skeletal muscle LIM protein 1 regulates integrin-mediated myoblast adhesion,spreading,and migration.Am J Physiol Cell Physiol.2003,284(3):C681-95.
16 McGrath MJ,Cottle DL,Nguyen MA,et al.Four and a half LIM protein 1 binds myosin binding protein c and regulates myosin filament formation and sarcomere assembly.J Biol Chem.2006,281(11):7666-83.
17 Morgan MJ,Madgwick AJA.The LIM proteins FHL1 and FHL3 are expressed differently in skeletal muscle.Biochem Biophys Res Commun.1999,255(2):245-50.
18 Johannessen M,M ler S,Hansen T,et al.The multifunctional roles of the four-and-a-half-LIM only protein FHL2.Cell Mol Life Sci.2006,63(3):268-284.
19 Morgan MJ,Madgwick AJ,Charleston B,et al.The developmental regulation of a novel muscle LIM-protein.Biochem Biophys Res Commun,1995,212:840-846.
20 Brown S,McGrath MJ,Ooms LM,et al.Characterization of two isoforms of the skeletal muscle LIM protein 1,SLIM1.J Biol Chem,1999,274:27083-9.
21 Shen Y,Jia Z,Nagele RG,et al.SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells.Cancer Res,2006,66:1543-52.
22 Schlaepfer DD,Hauck CR,Sieg DJ.Signaling through focal adhesion kinase.Prog Biophys Mol Biol,1999,71:435-78.
23 Sieg DJ,Hauck CR,Schlaepfer DD.Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration.J Cell Sci,1999,112 (16):2677-91.
24 Shen Y,Jia Z,Nagele RG,et al.Src uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells.Cancer Res,2006,66:1543-52.
25 Bhattacharjee A,Richards WG,Staunton J,et al.Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.Proc Natl Acad Sci USA,2001,98:13790-5.
26 Finley DJ,Arora N,Zhu B,et al.Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules.J Clin Endocrinol Metab,2004,89:3214-23.
27 Frykn(a|¨)s M,Wickenberg-Bolin U,G(o|¨)ransson H,et al.Molecular markers for discrimination of benign and malignant follicular thyroid tumors.Tumor Biol,2006,27:211-20.
28 Li X,Jia ZY,Shen YQ,et al.Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast,kidney,and prostate.Cancer Sci,2008,99 (7):1326-1333.
29 Lin J,Ding L,Jin R,et al.Four and a half LIM domains 1 (FHLl) and receptor interacting protein of 140kDa (RIP 140) interact and cooperate in estrogen signaling.Int J Biochem Cell Biol,2009,41(7):1613-8.
30 Ding L,Wang Z,Yan J,et al.Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway.J Clin Invest,2009,119(2):349-61.
31 Sakashita K,Mimori K,Tanaka F,et al.Clinical Significance of Loss of Fhl1 Expression in Human Gastric Cancer.Ann Surg Oncol,2008,15(8):2293-300.
32 Liotta LA,Kohn EC.The microenvironment of the tumorhost interface.Nature,2001,411:375-379.
33 Brabek J,Constancio SS,Shin NY,et al.CAS promotes invasiveness of Src-transformed cells.Oncogene,2004,23:7406-15.
34 Shin NY,Dise RS,Schneider-Mergener J,et al.Subsets of the major tyrosine phosphorylation sites in Crk-associated substrate (CAS) are sufficient to promote cell migration.J Biol Chem,2004,279:38331-7.
35 Goldberg GS,Alexander DB,Pellicena P,et al.Src phosphorylates Cas on tyrosine 253 to promote migration of transformed cells.J Biol Chem,2003 278:46533-40.
36 Dowsett M,Dunbier AK.Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.Clin Cancer Res,2008,14(24):8019-26.
37 Tiezzi DG,Andrade JM,Silva AR,et al.HER-2,p53,p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.BMC Cancer,2007,7:36-46.
38 Colleoni M,Viale G,Zahrieh D,et al.Chemotherapy is more effective in patients with breast cancer not expressingst eroid hormone receptors:a study of preoperative treatment.Clin Cancer Res,2004,10:6622-8.
39 RingA E,Smith IE,Ashley S,et al.Oestrogen receptor status,pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.Br J Cancer,2004,91:2012-7.
40 Lin J,Ding L,Jin R,et al.Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140kDa (RIP 140) interact and cooperate in estrogen signaling.Int J Biochem Cell Biol.2009,41(7):1613-8.
41 Zembutsu H,Suzuki Y,Sasaki A,et al.Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling.Int J Oncol.2009,34(2):361-70.
42 Chevallier B,Mignot L,Delozier T,et al.Phase Ⅱ study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer.Am J Clin Oncol,1992,15(5):395-8.
43 Robert J,Monnier A,Poutignat N,et al.A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.Cancer Chemother Pharmacol.1991,29(1):75-9.
44 Greish K,Nagamitsu A,Fang J,et al.Copoly (styrene-maleic acid)-pirarubicin micelles:high tumor-targeting efficiency with little toxicity.Bioconjug Chem.2005,16(1):230-6.
1.Johannessen M,M(?)iler S,Hansen T,et al.The multifunctional roles of the four-and-a-half-LIM only protein FHL2.Cell Mol Life Sci.2006,63(3):268-84.
2.Kleiber K,Strebhardt K,Martin B T.The biological relevance of FHL2 in tumnour cells and its role as a putative cancer target.Anticanccr Res,2007,27(1A):55-61.
3.Gabriel B,Fischer DC,Orlowska-Volk M,et al.Expression of the Transcriptional Coregulator FHL2 in Human Breast Cancer:A Clinicopathologic Study.J Soc Gynecol Investig.2006,13(1):70-75.
4.Kobayashi S,Shibata H,Yokota K,et al.FHL2,UBC9,and PIAS1 are Novel Estrogen Receptor a-Interacting Proteins.ENDOCRINE RESEARCH.2004,30(4):617-621.
5.Lee SW,Kim E J,Um SJ.FHL2 mediates p53-induced ranscriptional activation through a direct association with HIPK2.Biochemical and Biophysical Research Communications.2006,339:1056-1062.
6.丁丽华,熊志红,王朝云,等。FHL2抗体的制备及其在癌细胞和组织中表达的检测。细胞与分子免疫学杂志,2007,23(8):765-6。
7.Lauffart B,Sondarva GV,Gangisetty O,et al.Interaction of TACC proteins with the FHL family:implications for ERK signaling.J Cell Commun Signal.2007,1(1):5-15.
8.白玉杰,Seetha SV,Vamla B,等。BRCA2与 LIM 结构域蛋白 FHL2的相互作用。第四军医大学学报,2003,24(20):1845-1848.
9.Yan JH,Zhu JH,Zhong H J,et al.BRCA1 interacts with FHL2 and enhances FHL2transactivation function.FEBS Letters,2003,553:183-189.
10.Shen Y,Jia Z,Nagele RG,et al.SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells.Cancer Res,2006,66:1543-52.
11.Li X,Jia ZY,Shen YQ,et al.Coordinate suppression of Sdpr and Fhl1expression in tumors of the breast,kidney,and prostate.Cancer Sci.2008,99(7):1326-1333.
12.郭俊唐,周乃康,叶棋浓.FHL 家族与肿瘤的关系.生物技术通讯.2008,19(3):443-4.
1.Rustogi A,Budrukkar A,Dinshaw K,et al.Management of locally advanced breast cancer:evolution and current practice.J cancer Res Ther.2005,1(1):21-30.
2.包迎红,潘峰,周成槎.温州市鹿城区2003～2005年新发肿瘤发病分析,中华肿瘤防治杂志,2006,13(19):1449-1451.
3.王琳.上海市杨浦区1983～2001年常见恶性肿瘤发病趋势.中国肿瘤,2004,13(14):694-5.
4.Anees BC,Jamine LS,Charles RS,et al.Factors associated with surgical options for breast carcinoma.Cancer,2006,106:1462-6.
5.Newman LA,Kuerer HM.Advances in breast conservation therapy.J Clin Oncol,2005,23(8):1685-97.
6.Fisher B,Anderson S,Bryant J,et al.Twenty-year follow-up of a randomized trial comparing total mastectomy,lumpectomy,and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl J Med.2002,347(16):1233-41.
7.Chen AM,Meric-Bernstam F,Hunt KK,et al.Breast conservation after neoadjuvant chemotherapy:the MD Anderson cancer center experience.J Clin Oncol.2004,15;22(12):2303-12.
8.Singletary SE.Breast cancer surgery for the 21st century:the continuing evolution of minimally invasive treatment.Minerva Chir.2006,61(4):333-352.
9.American College of Radiology.Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma.J Am Coil Surg.2007,205(2):362-376.
10.Kaufmann P,Dauphine CE,Vargas MP,et al.Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery.Am Surg.2006 Oct;72(10):935-8.
11.Chen CY,Sun LM,Anderson BO.Paget Disease of the Breast:Changing Patterns of Incidence,Clinical Presentation,and Treatment in the U.S.CANCER.2006,107(7):1448-1458.
12.张保宁,邵志敏,乔新民,等。中国乳腺癌保乳治疗的前瞻性多中心研究。中华肿瘤杂志,2005,27(11):680-4。
13.王永胜,左文述,刘娟娟,等.乳腺癌前哨淋巴结活检替代腋窝清扫术前瞻性非随机对照临床研究.外科理论与实践,2006,11(2):104-107.
14.Rosing DK,Dauphine CE,Vargas MP,et al.Axillary regional recurrence after sentinel lymph node biopsy for breast cancer.Am Surg.2006 Oct;72(10):939-42.
15.Veronesi U,Paganelli G,Viale G,et al.Arandomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.N Engl J Med 2003;349:546-553.
16.Froud P J,ates D,chson SH,et al.Effect of time interval between breast conserving surgery and radiation therapy on ipsilateral breast recurrence.Int J Radiat Oncol Biol Phys,2000,46(2):363-72.
17.Faul C,Brufsky A,Gerszten K,et al.Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery.Eur J Cancer,2003,39(6):763-8.
18.修霞,Tripuraneni Prabhakar,Giap Huan Lin Ray,et al.早期乳腺癌保乳术后部分乳腺高剂量率后装加速照射的毒性反应及美容效果.中华放射肿瘤学杂志,2007,16(1):25-29.
19.DiFronzo LA,Tsai PI,Hwang JM,et al.Breast conserving surgery and accelerated partial breast irradiation using the MammoSite system:initial clinical exoerience.Arch Sure.2005.140(8):787-94.
20.江泽飞,宋三泰.蒽环类化疗药物治疗乳腺癌的新动向.中华肿瘤杂志,2005,27(4):193-195.
21.Heller W,Mazhar D,Ward R,et al.Neoadjuvant 5-fluorouracil,epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.Oncol Rep.2007 Jan;17(1):253-9.
22.Gonzalez-Angulo AM,Morales-Vasquez F,Hortobagyi GN.Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol.2007,608:1-22.
23.Fisher B,Jeong JH,Bryant J,et al.BuImpact of systemic treatment on local control for patients with lymphnode negative breast cancer treated wirh breast conservation therapy.J Clin Oncol,2001,19(8):2240-
24.张斌.乳腺癌新辅助内分泌治疗.中国癌症杂志,2006,16(9):689-692.
25.秦玉坤,李维廉.芳香化酶抑制剂在乳腺癌新辅助治疗中的研究进展.临床外科杂志,2006,14(1):32-33.
26.Thomas JS,Julian HS,Green RV,et al.Histopathology of breast carcinoma following neoadjuvant systemic therapy:a common association between letrozole therapy and central scarring.Histopathology.2007 Aug;51(2):219-26.
27.Gage I,Schnitt SJ,Nixon A J,et al.Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy.Cancer. 1996,78(9):1921-8.
2 Olopade OI,Grushko TA,Nanda R,et al.Advances in breast cancer:pathways to personalized medicine.Clin Cancer Res.2008,14(24):7988-99.
3 Mauri D,Pavlidis N,Ioannidis JP:Neoadjuvant versus adjuvant systemic treatment in breast cancer:A meta-analysis.J Natl Cancer Inst.2005,97:188-194.
4 Pritchard KI,Messersmith H,Elavathil L,et al.HER-2 and topoisomerase Ⅱ as predictors of response to chemotherapy.J Clin Oncol.2008,26(5):736-44.
5 Rody A,Kam T,G(?)tje R,et al.Gene expression profiling of breast cancer patients treated with docetaxel,doxorubicin,and cyclophosphamide within the GEPARTRIO trial:HER-2,but not topoisomerase Ⅱ alpha and microtubule-associated protein tau,is highly predictive of tumor response.Breast,2007,16(1):86-93.
6 Li X,Jia ZY,Shen YQ,et al.Coordinate suppression of Sdpr and Fhl1expression in tumors of the breast,kidney,and prostate.Cancer Sci,2008,99(7):1326-1333.
7 杨学宁,吴一龙.实体瘤治疗疗效评价标准——EC I ST.循证医学,2004,4(2):85-111.
8 Kang MA,Jeoung NH,Kim JY,et al.Up-regulation of skeletal muscle LIM protein 1 gene by 25-hydroxycholesterol may mediate morphological changes of rat aortic smooth muscle cells.Life Sciences,2007,80:460-467.
9 Michelsen JW,Sewell AK,Louis HA et al.Mutational analysis of the metal sites in an LIM domain.J Biol Chem 1994;269:11 108-13.
10 Schmeichel KL,Beckerle MC.Molecular dissection of a LIM domain.Mol Biol Cell 1997;8:219-30
11 Kadrmas JL,Beckerle MC.The LIM domain:from the cytoskeleton to the nucleus.Nat Rev Mol Cell Biol 2004;5:920-31.
12 Schmeichel KL,Beckerle MC.The LIM domain is a modular proteinbinding interface.Cell,1994,79:211-19.
13 Feuerstein R,Wang X,Song D,Cooke NE,Liebhaber SA.The LIM/double zinc-finger motif functions as a protein dimerization domain.Proc Natl Acad Sci USA 1994;91:10 655-9.
14 Morgan MJ,Whawell SA.The structure of the human LIM protein ACT gene and its expression in tumor cell lines.Biochemical and Biophysical Research Communications,2000,273 (2):776-783.
15 Robinson PA,Brown S,McGrath MJ,et al.Skeletal muscle LIM protein 1 regulates integrin-mediated myoblast adhesion,spreading,and migration.Am J Physiol Cell Physiol.2003,284(3):C681-95.
16 McGrath MJ,Cottle DL,Nguyen MA,et al.Four and a half LIM protein 1 binds myosin binding protein c and regulates myosin filament formation and sarcomere assembly.J Biol Chem.2006,281(11):7666-83.
17 Morgan MJ,Madgwick AJA.The LIM proteins FHL1 and FHL3 are expressed differently in skeletal muscle.Biochem Biophys Res Commun.1999,255(2):245-50.
18 Johannessen M,M ler S,Hansen T,et al.The multifunctional roles of the four-and-a-half-LIM only protein FHL2.Cell Mol Life Sci.2006,63(3):268-284.
19 Morgan MJ,Madgwick AJ,Charleston B,et al.The developmental regulation of a novel muscle LIM-protein.Biochem Biophys Res Commun,1995,212:840-846.
20 Brown S,McGrath MJ,Ooms LM,et al.Characterization of two isoforms of the skeletal muscle LIM protein 1,SLIM1.J Biol Chem,1999,274:27083-9.
21 Shen Y,Jia Z,Nagele RG,et al.SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells.Cancer Res,2006,66:1543-52.
22 Schlaepfer DD,Hauck CR,Sieg DJ.Signaling through focal adhesion kinase.Prog Biophys Mol Biol,1999,71:435-78.
23 Sieg DJ,Hauck CR,Schlaepfer DD.Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration.J Cell Sci,1999,112 (16):2677-91.
24 Shen Y,Jia Z,Nagele RG,et al.Src uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells.Cancer Res,2006,66:1543-52.
25 Bhattacharjee A,Richards WG,Staunton J,et al.Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.Proc Natl Acad Sci USA,2001,98:13790-5.
26 Finley DJ,Arora N,Zhu B,et al.Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules.J Clin Endocrinol Metab,2004,89:3214-23.
27 Frykn(a|¨)s M,Wickenberg-Bolin U,G(o|¨)ransson H,et al.Molecular markers for discrimination of benign and malignant follicular thyroid tumors.Tumor Biol,2006,27:211-20.
28 Li X,Jia ZY,Shen YQ,et al.Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast,kidney,and prostate.Cancer Sci,2008,99 (7):1326-1333.
29 Lin J,Ding L,Jin R,et al.Four and a half LIM domains 1 (FHLl) and receptor interacting protein of 140kDa (RIP 140) interact and cooperate in estrogen signaling.Int J Biochem Cell Biol,2009,41(7):1613-8.
30 Ding L,Wang Z,Yan J,et al.Human four-and-a-half LIM family members suppress tumor cell growth through a TGF-beta-like signaling pathway.J Clin Invest,2009,119(2):349-61.
31 Sakashita K,Mimori K,Tanaka F,et al.Clinical Significance of Loss of Fhl1 Expression in Human Gastric Cancer.Ann Surg Oncol,2008,15(8):2293-300.
32 Liotta LA,Kohn EC.The microenvironment of the tumorhost interface.Nature,2001,411:375-379.
33 Brabek J,Constancio SS,Shin NY,et al.CAS promotes invasiveness of Src-transformed cells.Oncogene,2004,23:7406-15.
34 Shin NY,Dise RS,Schneider-Mergener J,et al.Subsets of the major tyrosine phosphorylation sites in Crk-associated substrate (CAS) are sufficient to promote cell migration.J Biol Chem,2004,279:38331-7.
35 Goldberg GS,Alexander DB,Pellicena P,et al.Src phosphorylates Cas on tyrosine 253 to promote migration of transformed cells.J Biol Chem,2003 278:46533-40.
36 Dowsett M,Dunbier AK.Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.Clin Cancer Res,2008,14(24):8019-26.
37 Tiezzi DG,Andrade JM,Silva AR,et al.HER-2,p53,p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.BMC Cancer,2007,7:36-46.
38 Colleoni M,Viale G,Zahrieh D,et al.Chemotherapy is more effective in patients with breast cancer not expressingst eroid hormone receptors:a study of preoperative treatment.Clin Cancer Res,2004,10:6622-8.
39 RingA E,Smith IE,Ashley S,et al.Oestrogen receptor status,pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.Br J Cancer,2004,91:2012-7.
40 Lin J,Ding L,Jin R,et al.Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140kDa (RIP 140) interact and cooperate in estrogen signaling.Int J Biochem Cell Biol.2009,41(7):1613-8.
41 Zembutsu H,Suzuki Y,Sasaki A,et al.Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling.Int J Oncol.2009,34(2):361-70.
42 Chevallier B,Mignot L,Delozier T,et al.Phase Ⅱ study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with advanced breast cancer.Am J Clin Oncol,1992,15(5):395-8.
43 Robert J,Monnier A,Poutignat N,et al.A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.Cancer Chemother Pharmacol.1991,29(1):75-9.
44 Greish K,Nagamitsu A,Fang J,et al.Copoly (styrene-maleic acid)-pirarubicin micelles:high tumor-targeting efficiency with little toxicity.Bioconjug Chem.2005,16(1):230-6.
1.Johannessen M,M(?)iler S,Hansen T,et al.The multifunctional roles of the four-and-a-half-LIM only protein FHL2.Cell Mol Life Sci.2006,63(3):268-84.
2.Kleiber K,Strebhardt K,Martin B T.The biological relevance of FHL2 in tumnour cells and its role as a putative cancer target.Anticanccr Res,2007,27(1A):55-61.
3.Gabriel B,Fischer DC,Orlowska-Volk M,et al.Expression of the Transcriptional Coregulator FHL2 in Human Breast Cancer:A Clinicopathologic Study.J Soc Gynecol Investig.2006,13(1):70-75.
4.Kobayashi S,Shibata H,Yokota K,et al.FHL2,UBC9,and PIAS1 are Novel Estrogen Receptor a-Interacting Proteins.ENDOCRINE RESEARCH.2004,30(4):617-621.
5.Lee SW,Kim E J,Um SJ.FHL2 mediates p53-induced ranscriptional activation through a direct association with HIPK2.Biochemical and Biophysical Research Communications.2006,339:1056-1062.
6.丁丽华,熊志红,王朝云,等。FHL2抗体的制备及其在癌细胞和组织中表达的检测。细胞与分子免疫学杂志,2007,23(8):765-6。
7.Lauffart B,Sondarva GV,Gangisetty O,et al.Interaction of TACC proteins with the FHL family:implications for ERK signaling.J Cell Commun Signal.2007,1(1):5-15.
8.白玉杰,Seetha SV,Vamla B,等。BRCA2与 LIM 结构域蛋白 FHL2的相互作用。第四军医大学学报,2003,24(20):1845-1848.
9.Yan JH,Zhu JH,Zhong H J,et al.BRCA1 interacts with FHL2 and enhances FHL2transactivation function.FEBS Letters,2003,553:183-189.
10.Shen Y,Jia Z,Nagele RG,et al.SRC uses Cas to suppress Fhl1 in order to promote nonanchored growth and migration of tumor cells.Cancer Res,2006,66:1543-52.
11.Li X,Jia ZY,Shen YQ,et al.Coordinate suppression of Sdpr and Fhl1expression in tumors of the breast,kidney,and prostate.Cancer Sci.2008,99(7):1326-1333.
12.郭俊唐,周乃康,叶棋浓.FHL 家族与肿瘤的关系.生物技术通讯.2008,19(3):443-4.
1.Rustogi A,Budrukkar A,Dinshaw K,et al.Management of locally advanced breast cancer:evolution and current practice.J cancer Res Ther.2005,1(1):21-30.
2.包迎红,潘峰,周成槎.温州市鹿城区2003～2005年新发肿瘤发病分析,中华肿瘤防治杂志,2006,13(19):1449-1451.
3.王琳.上海市杨浦区1983～2001年常见恶性肿瘤发病趋势.中国肿瘤,2004,13(14):694-5.
4.Anees BC,Jamine LS,Charles RS,et al.Factors associated with surgical options for breast carcinoma.Cancer,2006,106:1462-6.
5.Newman LA,Kuerer HM.Advances in breast conservation therapy.J Clin Oncol,2005,23(8):1685-97.
6.Fisher B,Anderson S,Bryant J,et al.Twenty-year follow-up of a randomized trial comparing total mastectomy,lumpectomy,and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl J Med.2002,347(16):1233-41.
7.Chen AM,Meric-Bernstam F,Hunt KK,et al.Breast conservation after neoadjuvant chemotherapy:the MD Anderson cancer center experience.J Clin Oncol.2004,15;22(12):2303-12.
8.Singletary SE.Breast cancer surgery for the 21st century:the continuing evolution of minimally invasive treatment.Minerva Chir.2006,61(4):333-352.
9.American College of Radiology.Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma.J Am Coil Surg.2007,205(2):362-376.
10.Kaufmann P,Dauphine CE,Vargas MP,et al.Success of neoadjuvant chemotherapy in conversion of mastectomy to breast conservation surgery.Am Surg.2006 Oct;72(10):935-8.
11.Chen CY,Sun LM,Anderson BO.Paget Disease of the Breast:Changing Patterns of Incidence,Clinical Presentation,and Treatment in the U.S.CANCER.2006,107(7):1448-1458.
12.张保宁,邵志敏,乔新民,等。中国乳腺癌保乳治疗的前瞻性多中心研究。中华肿瘤杂志,2005,27(11):680-4。
13.王永胜,左文述,刘娟娟,等.乳腺癌前哨淋巴结活检替代腋窝清扫术前瞻性非随机对照临床研究.外科理论与实践,2006,11(2):104-107.
14.Rosing DK,Dauphine CE,Vargas MP,et al.Axillary regional recurrence after sentinel lymph node biopsy for breast cancer.Am Surg.2006 Oct;72(10):939-42.
15.Veronesi U,Paganelli G,Viale G,et al.Arandomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.N Engl J Med 2003;349:546-553.
16.Froud P J,ates D,chson SH,et al.Effect of time interval between breast conserving surgery and radiation therapy on ipsilateral breast recurrence.Int J Radiat Oncol Biol Phys,2000,46(2):363-72.
17.Faul C,Brufsky A,Gerszten K,et al.Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery.Eur J Cancer,2003,39(6):763-8.
18.修霞,Tripuraneni Prabhakar,Giap Huan Lin Ray,et al.早期乳腺癌保乳术后部分乳腺高剂量率后装加速照射的毒性反应及美容效果.中华放射肿瘤学杂志,2007,16(1):25-29.
19.DiFronzo LA,Tsai PI,Hwang JM,et al.Breast conserving surgery and accelerated partial breast irradiation using the MammoSite system:initial clinical exoerience.Arch Sure.2005.140(8):787-94.
20.江泽飞,宋三泰.蒽环类化疗药物治疗乳腺癌的新动向.中华肿瘤杂志,2005,27(4):193-195.
21.Heller W,Mazhar D,Ward R,et al.Neoadjuvant 5-fluorouracil,epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer.Oncol Rep.2007 Jan;17(1):253-9.
22.Gonzalez-Angulo AM,Morales-Vasquez F,Hortobagyi GN.Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol.2007,608:1-22.
23.Fisher B,Jeong JH,Bryant J,et al.BuImpact of systemic treatment on local control for patients with lymphnode negative breast cancer treated wirh breast conservation therapy.J Clin Oncol,2001,19(8):2240-
24.张斌.乳腺癌新辅助内分泌治疗.中国癌症杂志,2006,16(9):689-692.
25.秦玉坤,李维廉.芳香化酶抑制剂在乳腺癌新辅助治疗中的研究进展.临床外科杂志,2006,14(1):32-33.
26.Thomas JS,Julian HS,Green RV,et al.Histopathology of breast carcinoma following neoadjuvant systemic therapy:a common association between letrozole therapy and central scarring.Histopathology.2007 Aug;51(2):219-26.
27.Gage I,Schnitt SJ,Nixon A J,et al.Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy.Cancer. 1996,78(9):1921-8.